Global Ischemic Heart Disease Market, By Disease (Angina Pectoris, Myocardial Infarction), Drug Class (Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, ACE Inhibitors, ARBs, Vasodilators, Antithrombotic Agents), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa) Industry Trends and Forecast to 2028
The ischemic heart disease market is expected to witness market growth at a rate of 4.67% in the forecast period of 2021 to 2028 and is expected to reach USD 5,745.63 million by 2028. Data Bridge Market Research report on ischemic heart disease market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the market’s growth. The increasing prevalence of cardiovascular diseases is escalating the growth of ischemic heart disease market.
Ischemic heart disease (IHD) refers to an abnormal condition of the heart which often is seen during excitement and exertion as the heart needs more blood supply. A blockage of the arteries that supply blood to the heart causes the condition to occur which is due to the buildup of plaque in the arteries. The lack of sufficient blood supply may result in recurrent chest pain and discomfort leading to a condition called angina pectoris
The increasing number of people suffering from IHD acts as one of the major factors driving the growth of the ischemic heart disease market. The high prevalence of chronic conditions such as diabetes, hypertension and cholesterol levels increasing the risk of suffering from cardiovascular diseases and rise in mortality rate across the globe accelerates the ischemic heart disease market growth. The surge in the development of more advanced IHD drugs and government initiatives in the form of funding for diagnosis, treatment and research and their initiative programs to increase the awareness toward disease among the population further influence the ischemic heart disease market. Additionally, improving healthcare system, growth in population, increase in the occurrence of heart problems due to obesity and lack of physical activities and rise in healthcare expenditure positively affect the ischemic heart disease market. Furthermore, technological advancement and product innovations extend profitable opportunities to the ischemic heart disease market players in the forecast period of 2021 to 2028.
On the other hand, high cost associated with the treatment and the regular uncertainty seen in reimbursement policies are the factors expected to obstruct the ischemic heart disease market growth. The rise in concerns regarding side effects on the body is projected to challenge the ischemic heart disease market in the forecast period of 2021-2028.
This ischemic heart disease market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on ischemic heart disease market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Ischemic Heart Disease Market Scope and Market Size
The ischemic heart disease market is segmented on the basis of disease and drug class. The growth amongst these segments will help you analyze meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- On the basis of disease, the ischemic heart disease market is segmented into angina pectoris and myocardial infarction. Angina pectoris is further segmented into stable angina, unstable angina and prinzmetal's angina. Myocardial infarction is further segmented into STEMI and NSTEMI.
- On the basis of drug class, the ischemic heart disease market is segmented into anti-dyslipidemic drugs, calcium channel blockers, beta-blockers, ACE inhibitors, ARBs, vasodilators and antithrombotic agents.
Global Ischemic Heart Disease Market Country Level Analysis
The ischemic heart disease market is analyzed and market size insights and trends are provided by country, disease and drug class as referenced above.
The countries covered in the global ischemic heart disease market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America and Europe dominate the ischemic heart disease market because of the high prevalence of ischemic disease and cardiovascular diseases. Asia-Pacific is expected to witness highest CAGR in the forecast period of 2021-2028 because of the rising prevalence of heart diseases and strokes and increasing awareness towards CAD in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The ischemic heart disease market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for ischemic heart disease market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the ischemic heart disease market. The data is available for historic period 2011 to 2019.
Competitive Landscape and Ischemic Heart Disease Market Share Analysis
The ischemic heart disease market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to ischemic heart disease market.
The major players covered in the ischemic heart disease market report are Amgen Inc., AstraZeneca, Bayer AG, Novartis AG, Gilead Sciences, Inc, GlaxoSmithKline plc., Pfizer Inc., Teva Pharmaceutical Industries Ltd, Cardurion Pharmaceuticals, Cardior Pharmaceuticals, Actelion Pharmaceuticals Ltd, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, CYTOKINETICS, INC., Eli Lilly and Company, Merck Sharp & Dohme Corp., Quantum Genomics, RENOVA, SERVIER LABORATORIES, Stealth BioTherapeutics Inc., Sanofi, Mylan N.V., Bausch Health Companies Inc. among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Customization Available : Global Ischemic Heart Disease Market
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.